Testing effectiveness (Phase 2)Study completedNCT00267722
What this trial is testing
Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's Disease
Who this might be right for
Crohn's Disease
Facet Biotech 18
Showing 20 of 233 results